Matt Hellmann: The detection of MRD by assaying ctDNA in patients with cancer
Matt Hellmann, Vice President of Early Oncology Development at AstraZeneca, shared an article Roy S. Herbst and colleagues on LinkedIn:
“Our team just published new data in Nature Medicine on the detection of molecular residual disease (MRD) by assaying circulating tumor DNA (ctDNA) in patients with cancer – the first comprehensive longitudinal analysis of MRD of its kind in non-small cell lung cancer (NSCLC). Monitoring for MRD this way has the potential to improve patient outcomes by determining the patients who may benefit from additional therapy and those who may not.
At AstraZeneca, we are focused on treating cancer earlier and smarter and believe that ctDNA analysis can help transform cancer care from a patient’s earliest stages of screening through their long-term follow-up. Translational science is at the heart of our efforts in oncology research and development and underpins development of next generation diagnostics and predictive biomarkers.
Our efforts in transforming cancer outcomes will be enhanced by our ability to understand tumor biology, predict treatment response and resistance, and find new ways to attack cancer from multiple angles.
Congratulations to the team on publishing such impactful work as we continue to push the boundaries of science to transform cancer outcomes.”
Authors: Roy S. Herbst et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023